The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, ...

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

Novo Nordisk and Eli Lilly (with its Zepbound) are the two reigning kings on the U.S. market these days. There will be more contenders; Viking Therapeutics, in particular, is in the later stages of ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...

The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...